PTIXW — Protagenic Therapeutics, Inc.

Summary of Protagenic Therapeutics (PTIXW) Q4 2023 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2023 R&D Expenditure: $1.0 million, a 301% increase from $258,000 in Q4 2022, driven by the initiation of the clinical trial for PT00114.
• G&A Expenses: $201,000, down 50% compared to the same quarter last year, primarily due to minimal stock-based compensation.
• Net Loss for Q4: $1.2 million, compared to $656,000 in Q4 2022.
• Full Year 2023 R&D Spending: $3.3 million, up 109% from $1.6 million in 2022.
• Full Year Net Loss: $4.5 million, a 27% increase from 2022, largely due to higher R&D costs.
• Cash Position: Ended 2023 with $4.1 million in cash, down from $8.0 million at the end of 2022, but management believes this is sufficient to fund the Phase 1 clinical trial.

2. Strategic Updates and Business Highlights:

• Clinical Development: Initiated the first-ever clinical trial of PT00114, a neuropeptide drug candidate aimed at treating depression, anxiety, PTSD, and addiction.
• Mechanism of Action: PT00114 is designed to target specific neuronal pathways involved in stress response, potentially offering fewer side effects compared to existing treatments.
• Collaboration: Engaging with experts, including Dr. Maurizio Fava from Harvard, to guide clinical trial design and execution.

3. Forward Guidance and Outlook:

• 2024 Focus: Efficient execution of Phase 1 clinical trials and preparation for proof-of-concept studies in various neuropsychiatric disorders.
• Clinical Trial Timeline: Enrollment for the single ascending dose (SAD) study is expected to complete by the end of April 2024, with data readout anticipated by mid-May. The multiple ascending dose (MAD) study will begin immediately after the SAD study completion, with results expected in early Q3 2024.

4. Bad News, Challenges, or Points of Concern:

• Increased Losses: The company reported a larger net loss year-over-year, raising concerns about financial sustainability as R&D spending increases.
• Cash Burn Rate: The significant decrease in cash reserves may necessitate future fundraising or strategic partnerships to support ongoing clinical development.
• Regulatory Risks: The need for regulatory approval for Phase 2 studies adds uncertainty, although management is confident due to the safety profile observed so far.

5. Notable Q&A Insights:

• Clinical Trial Data: Management confirmed that cortisol levels will be measured and reported alongside results from the SAD and MAD studies, providing insights into the neuroprotective effects of PT00114.
• Regulatory Steps: The Phase 2 protocol is being finalized for submission to regulatory agencies, with confidence in approval based on the drug's safety profile.
• Trial Design: The Phase 2 studies may adopt a "basket trial" approach to assess efficacy across various neuropsychiatric conditions, enhancing the potential for broader applicability of PT00114.

Overall, Protagenic Therapeutics is positioned at a critical juncture with the advancement of PT00114 into clinical trials, while facing financial and regulatory challenges that will require careful navigation in the coming year.